In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects

Br J Cancer. 2003 Dec 15;89(12):2305-11. doi: 10.1038/sj.bjc.6601431.

Abstract

Ecteinascidin 743 (ET-743) is a new marine-derived agent with promising activity against a number of solid tumours. In four human tumour cell lines, the interaction between ET-743 and radiation was investigated in relation to the effects of ET-743 on the cell cycle, in vitro. Cell survival was measured based on quantitative staining of cellular protein by sulforhodamine B. A 24 h treatment with ET-743 before radiation resulted in a moderate increase in radiosensitivity in three out of four cell lines. Dose enhancement factors > or =1.8 were observed for concentrations resulting in 52, 46 and 30% cell kill in ECV304, H292 and CAL-27, respectively, whereas in A549 no radiosensitisation was observed (no significant increase in radiosensitivity). According to the combination index analysis, synergism was observed only in ECV304 and CAL-27 cells. A 24 h incubation with ET-743 resulted in a concentration-dependent G2/M block, which might explain the moderate radiosensitising effects in ECV304 and H292. The lack of radiosensitisation in A549 might be due to the S phase delay preceding the G2/M block at the moment of radiation, which only occurred in this cell line. In conclusion, ET-743 has moderate cell line-dependent radiosensitising properties; however, only when cytotoxic concentrations of ET-743 are used. In one of the four cell lines tested, no radiosensitisation was observed.

MeSH terms

  • Antineoplastic Agents, Alkylating / pharmacology*
  • Carcinoma / drug therapy
  • Carcinoma / radiotherapy
  • Carcinoma / therapy*
  • Cell Cycle / drug effects*
  • Cell Cycle / radiation effects
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Combined Modality Therapy
  • Dioxoles / pharmacology*
  • Humans
  • Isoquinolines / pharmacology*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / radiotherapy
  • Lung Neoplasms / therapy
  • Radiation-Sensitizing Agents / pharmacology*
  • Tetrahydroisoquinolines
  • Tongue Neoplasms / drug therapy
  • Tongue Neoplasms / radiotherapy
  • Tongue Neoplasms / therapy
  • Trabectedin
  • Urinary Bladder Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / radiotherapy
  • Urinary Bladder Neoplasms / therapy

Substances

  • Antineoplastic Agents, Alkylating
  • Dioxoles
  • Isoquinolines
  • Radiation-Sensitizing Agents
  • Tetrahydroisoquinolines
  • Trabectedin